Retatrutide — Research Guide
Retatrutide is an investigational triple-agonist peptide that binds the GLP-1, GIP, and glucagon receptors. It is one of the most cited compounds in current incretin-class metabolic-signaling research and is studied alongside earlier dual and single agonists (Tirzepatide, Semaglutide) to isolate the contribution of glucagon co-agonism.
Research Use Only — Not FDA-Approved
Orion compounds are for in-vitro laboratory research only and are not for human consumption.
Product
Retatrutide 10mg
Purity
99.0%
CAS
2381089-83-2
Single
$54.99
10-pack/vial
$41.24
Chemistry & identity
Retatrutide (CAS 2381089-83-2, MW 4625.27 g/mol) is a synthetic peptide produced by solid-phase peptide synthesis. Each Orion batch is tested by reversed-phase HPLC for purity and confirmed by mass spectrometry against the theoretical molecular weight. The batch-specific Certificate of Analysis records the measured purity value (specification ≥ 99.0%).
Research applications
- Triple-receptor binding affinity and selectivity profiling (GLP-1R / GIPR / GCGR)
- Receptor-recruitment kinetics in receptor-expressing cell models
- Comparative pharmacology against single-target (Semaglutide) and dual-target (Tirzepatide) controls
- cAMP signaling cascade activation studies
- Energy-homeostasis pathway modeling in cell-line assays
Stability & storage
Lyophilized Retatrutide is stable when stored at −20°C protected from light and moisture. After reconstitution with bacteriostatic water, published in-solution stability supports refrigerated storage (2–8°C) for short-term research timecourse work. See the half-life calculator for predicted in-solution decay using published literature ranges.
Published half-life range
144h midpoint (lit. 120h – 168h)
Source: Coskun et al., Cell Metabolism 2022. See the half-life calculator for predicted in-solution decay over time.
Direct comparisons
Related research guides
Tirzepatide — Research Guide
Tirzepatide is a dual GIP / GLP-1 receptor agonist peptide. It is widely used in incretin-class metabolic-signaling research as the reference dual-agonist control alongside single-target agonists (Semaglutide) and triple-target agonists (Retatrutide).
Semaglutide — Research Guide
Semaglutide is a single-target GLP-1 receptor agonist peptide and the canonical reference compound for GLP-1-receptor research. As the longest-running modern GLP-1 analogue with extensive literature, it serves as the baseline against which newer dual- and triple-agonists are compared.
FAQ
How is Retatrutide different from Tirzepatide?
Tirzepatide is a dual GIP/GLP-1 receptor agonist. Retatrutide adds glucagon-receptor agonism, giving it triple-receptor coverage. The added glucagon arm is hypothesized to drive distinct metabolic-signaling profiles in research models compared to dual or single agonists.
What purity does Orion ship?
≥ 99.0% by reversed-phase HPLC, with the measured value recorded on the batch-specific COA. Identity is confirmed by mass spectrometry against the theoretical molecular weight of 4625.27 g/mol.
Can this be shipped to my state?
Orion does not ship compounded GLP-1-class compounds to CA, NY, TX, LA, or MS. See the restricted substances policy for the full list and rationale.
Is this for human use?
No. Retatrutide is for in-vitro laboratory research only. It is not FDA-approved and is not for human consumption.